Who Paid My Doc
Thomas Schnitzer
Neuromusculoskeletal Medicine, Sports Medicine Chicago, IL Medical Doctor
NPI 1588649461 CMS profile 1063101
345 E Superior St, Chicago, IL 60611
General payments
$337,461
Research payments
$142,981
Ownership & investment interest
$0
Research they led as principal investigator
$9,609,330
Through program year 2025, Thomas Schnitzer of Chicago, IL is reported in the CMS Open Payments database as having received $337,461 across 262 general payments and $142,981 in research payments paid to them. Separately, studies naming them as principal investigator received $9,609,330 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Neuromusculoskeletal Medicine, Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $16,034 | 21 | |
| 2024 | General | $18,915 | 30 | |
| 2024 | Research | $63,988 | 7 | |
| 2023 | General | $48,233 | 45 | |
| 2023 | Research | $3,815 | 4 | |
| 2022 | General | $15,564 | 6 | |
| 2022 | Research | $27,446 | 11 | |
| 2021 | General | $83,736 | 15 | |
| 2021 | Research | $28,110 | 16 | |
| 2020 | General | $48,294 | 52 | |
| 2020 | Research | $18,609 | 25 | |
| 2019 | General | $106,684 | 93 | |
| 2019 | Research | $1,012 | 8 |
Beside peers
- Thomas Schnitzer
- Neuromusculoskeletal Medicine, Sports Medicine median
- Middle half of Neuromusculoskeletal Medicine, Sports Medicine
- National median
In program year 2025, general payments to Thomas Schnitzer were reported at $16,034. Among 69 Neuromusculoskeletal Medicine, Sports Medicine profiles paid that year, the median was $125 and the middle half received between $37 and $473.
Show as a table
| Year | Thomas Schnitzer | Neuromusculoskeletal Medicine, Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $106,684 | $152 | $43–$474 | $163 |
| 2020 | $48,294 | $113 | $31–$725 | $114 |
| 2021 | $83,736 | $167 | $50–$469 | $132 |
| 2022 | $15,564 | $132 | $46–$572 | $149 |
| 2023 | $48,233 | $109 | $39–$366 | $160 |
| 2024 | $18,915 | $115 | $37–$321 | $164 |
| 2025 | $16,034 | $125 | $37–$473 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
333 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Neuromusculoskeletal Medicine, Sports Medicine in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Neuromusculoskeletal Medicine, Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.